Category Archives: Regulatory Strategy

Time to Approval and the Metrics of Facilitated Regulatory Pathways

By Dr. Jack Snyder, RAC (US, EU, CA, GS), Asst. Managing Director and Clinical Research Physician at Cato Research “Early access pathways” for biomedical product marketing approval have attracted substantial attention recently, as Sarepta Therapeutics’ drug Exondys (eteplirsen) gained accelerated … Continue reading

Posted in Cato Research, Medical Research, Regulatory Affairs, Regulatory Strategy, Regulatory Submissions | Tagged , , | Leave a comment

New FDA Guidances for July 2017

By Michelle Villasmil, Ph.D., RAC (US), Regulatory Scientist at Cato Research FDA draft and final guidances released from CDER, CBER, and CDRH and Manual of Policies and Procedures (MAPPs) of interest released from CDER in July 2017 are posted. In … Continue reading

Posted in FDA, Regulatory Affairs, Regulatory Strategy, Regulatory Submissions | Tagged , , | Comments Off on New FDA Guidances for July 2017

New FDA Guidances for June 2017

By Michelle Villasmil, Ph.D., RAC (US), Regulatory Scientist at Cato Research FDA draft and final guidances released from CDER, CBER, and CDRH and Manual of Policies and Procedures (MAPPs) of interest released from CDER in June 2017 are posted. In … Continue reading

Posted in Cato Research, FDA, Medical Research, Regulatory Strategy, Regulatory Submissions | Tagged , , | Comments Off on New FDA Guidances for June 2017

New FDA Guidances for March and April 2017

By Joanne McNelis, Ph.D., Clinical Strategy Scientist at Cato Research FDA draft and final guidances, released from CDER, CBER, and CDRH, and Manual of Policies and Procedures (MAPPs) of interest, released from CDER in March and April are posted. In … Continue reading

Posted in Drug Development, FDA, Regulatory Strategy, Regulatory Submissions | Tagged , , | Comments Off on New FDA Guidances for March and April 2017

A New Expedited Review Designation: Regenerative Advanced Therapy

By Michelle Villasmil, Ph.D., RAC (U.S.), Regulatory Scientist at Cato Research One of the many changes brought by the 21st Century Cures Act is the new expedited review designation entitled Regenerative Advanced Therapy (with the unfortunate acronym of RAT). FDA … Continue reading

Posted in Cato Research, Drug Development, Medical Research, Regulatory Strategy, Regulatory Submissions | Tagged , , , , | Comments Off on A New Expedited Review Designation: Regenerative Advanced Therapy